Positive Outcomes for Patients Using AUSTEDO
In a new cohort of adults, many participants reported positive changes in their daily lives while using AUSTEDO (deutetrabenazine) or AUSTEDO XR (deutetrabenazine). This comes from the ongoing real-world IMPACT-TD Registry, indicating that nearly 77% of those enrolled noticed improvements related to their experience with tardive dyskinesia (TD). The ongoing commitment of Teva Pharmaceuticals, a well-known player in the biopharmaceutical sector, emphasizes understanding and addressing the unique challenges faced by individuals living with TD.
Impact on Mental Health
Furthermore, 85% of those participants utilizing AUSTEDO or AUSTEDO XR alongside their mental health medications reported no decline—rather, their conditions either remained stable or improved. This is a standout benefit of AUSTEDO, which is pivotal for patients dealing with both TD and concurrent mental health issues.
Study Findings from the IMPACT-TD Registry
Teva Pharmaceuticals, headquartered in both the U.S. and Israel, unveiled these significant findings during a congress focused on neuroscience education. As part of the interim analysis of the IMPACT-TD Registry, which is a Phase 4 study, the cohort comprised 27 adults. They were observed over three months using IMPACT-TD PRO, a comprehensive tool featuring 30 questions aimed at measuring patient-reported impacts in five important areas of their lives.
Results That Matter
The study revealed that participants noted substantial improvements in various aspects of their daily lives. These included a 77% improvement in speech and communication, 75% in eating, and 65% regarding psychosocial impacts. Activities of daily living and sleep/pain saw improvements of 59% and 50%, respectively. Additionally, a lower total motor score on the Abnormal Involuntary Movement Scale (AIMS) showcased a mean decrease of -2.9, illustrating a significant reduction in movement severity.
Understanding Tardive Dyskinesia
It is crucial to grasp what tardive dyskinesia (TD) entails. This chronic and debilitating movement disorder impacts around one-fourth of those undergoing certain mental health treatments, resulting in uncontrolled and repetitive movements that can greatly hinder a person’s quality of life.
AUSTEDO and AUSTEDO XR: Solutions with Purpose
AUSTEDO XR and AUSTEDO stand out as pioneering vesicular monoamine transporter 2 (VMAT2) inhibitors, first being authorized by the U.S. Food and Drug Administration for adults aiming to manage tardive dyskinesia as well as chorea tied to Huntington’s disease. While highlighting their efficacy, it’s important to note that safety and effectiveness in pediatric populations remain unestablished. The once-daily formulation of AUSTEDO XR offers a feasible regimen for patients seeking reliable treatment.
Safety Considerations and Monitoring
As with any medication, safety is paramount. For both AUSTEDO and AUSTEDO XR, patients with Huntington’s disease may face an increased risk of depression and suicidal ideation. Health professionals must balance these risks against the desire for symptom management and encourage regular monitoring of their patients to identify signs of mood changes or unusual behaviors.
What Patients Should Expect
Common reactions involve sedation, dry mouth, and fatigue, necessitating patients to be aware of how the medications affect their daily activities, especially tasks requiring significant mental acuity. Therefore, the emphasis must be placed on patient education and preparedness as they start their treatment journey with either AUSTEDO or AUSTEDO XR.
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has established its reputation by continually innovating across various therapeutic fields, including neuroscience. Its broad portfolio includes innovative medicines as well as generic and biosimilar products designed to address the diverse needs of patients globally. Teva plays a vital role in the pharmaceutical landscape, dedicated to enhancing healthcare outcomes for its consumers.
Frequently Asked Questions
What is AUSTEDO used for?
AUSTEDO is designed to treat tardive dyskinesia and chorea associated with Huntington’s disease in adults.
How does AUSTEDO impact quality of life?
Patients using AUSTEDO report significant improvements in movement control and overall daily activities.
What are common side effects of AUSTEDO?
Common side effects include sedation, dry mouth, and fatigue, which necessitate cautious use in daily activities.
Is AUSTEDO effective for all patients?
The effectiveness of AUSTEDO can vary by individual, and ongoing evaluations are crucial for optimizing treatment.
How can I contact Teva for more information?
For inquiries, individuals can reach out to Teva via email for more detailed information on their products and services.
